CTNM
CTNM clinical trials: Contineum Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Contineum Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 7
- Trials linked
- 7
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
CTNM on the catalyst calendar · CTNM registry changes
- Primary completion May 2028Sponsor estimatePhase 2NCT07284459Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary FibrosisContineum Therapeutics · Idiopathic Pulmonary FibrosisRecruitingCTNMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 20, 2026ActualPhase 1NCT06810245Study of PIPE-791 for Subjects With Chronic Osteoarthritis Pain or Chronic Low Back PainContineum Therapeutics · Chronic Osteoarthritis PainCompletedCTNMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 4, 2025ActualPhase 1NCT06683612PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPFContineum Therapeutics · Idiopathic Pulmonary Fibrosis (IPF)CompletedCTNMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 17, 2021ActualPhase 1/Phase 2NCT04462198Phase I/IIa Study Evaluating Safety and Efficacy of an Intratympanic Dose of PIPE-505 in Subjects With Hearing LossContineum Therapeutics · Sensorineural Hearing LossCompletedCTNMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 1, 2024ActualPhase 1NCT05983939Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of PIPE-791 and Food Effect in Healthy VolunteersContineum Therapeutics · Multiple SclerosisCompletedCTNMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 10, 2021ActualPhase 1NCT04941781PET Study to Determine the Relationship Between Plasma Concentrations and Muscarinic Type 1 Receptor (M1AChR) Occupancy of PIPE-307 in...Contineum Therapeutics · Multiple SclerosisCompletedCTNMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 1, 2021ActualPhase 1NCT04725175Phase I Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of of PIPE-307 and Food Effect in Healthy...Contineum Therapeutics · Multiple SclerosisCompletedCTNMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 7 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner